Nogest (Nomegestrol Acetate)

Nomegestrol acetate, the active ingredient in Nogest, is a progestogen presented as an oral tablet for oral use. It is employed as a hormonal contraceptive and as a progestogenic component in hormone replacement therapy for women of reproductive age and post‑menopausal patients.

GNH USA supplies Nogest as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nomegestrol acetate is used in hormonal regimens that modulate the progesterone pathway. - Oral contraception: prevents pregnancy by suppressing ovulation and altering cervical mucus. - Hormone replacement therapy: provides progestogenic support to estrogen therapy in menopausal women. - Endometrial protection: reduces the risk of estrogen‑induced endometrial hyperplasia during combined hormone replacement therapy.

Adverse reactions may occur with any hormonal agent.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: discomfort or swelling of the breasts. - Irregular bleeding: spotting or changes in menstrual flow.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Before initiating therapy, consider the following safety measures. - Assess thrombotic risk: evaluate personal or family history of clotting disorders. - Screen for liver disease: avoid use in severe hepatic impairment. - Monitor blood pressure: watch for new or worsening hypertension. - Avoid in pregnancy: contraindicated unless benefits outweigh risks. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Nomegestrol acetate may interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): may markedly reduce contraceptive efficacy. - Anticoagulants (warfarin): potential alteration of anticoagulant effect. - Antiepileptic drugs (carbamazepine): may diminish plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (ketoconazole): may increase plasma levels. - Antiretrovirals (ritonavir): can affect metabolism and efficacy. - Herbal supplements (St. John’s wort): may lower effectiveness of the contraceptive.